Table 8 SARS-CoV-2 breakthrough infections in chemotherapy and hematology treatment subgroups.
Period | Cohort | N | Number of cases | Sensitivity | Specificity | AUC | Optimal threshold (log10) | Optimal threshold (BAU/mL) |
|---|---|---|---|---|---|---|---|---|
E | Chemotherapy | 254 | 2 | 1.000 | 0.560 | 0.738 | 2.090 | 123.03 |
Hematology | 109 | 7 | 0.857 | 0.529 | 0.709 | 0.736 | 5.45 | |
F | Chemotherapy | 176 | 5 | 1.000 | 0.509 | 0.671 | 2.380 | 239.88 |
Hematology | 86 | 1 | 1.000 | 0.506 | 0.753 | 0.736 | 5.45 | |
G | Chemotherapy | 198 | 37 | 0.838 | 0.547 | 0.736 | 3.400 | 2511.87 |
Hematology | 109 | 30 | 0.733 | 0.532 | 0.547 | 2.130 | 134.90 | |
H | Chemotherapy | 80 | 8 | 0.625 | 0.500 | 0.490 | 3.360 | 2290.87 |
Hematology | 59 | 4 | 1.000 | 0.491 | 0.764 | 2.230 | 169.82 | |
I | Chemotherapy | 135 | 9 | 0.556 | 0.643 | 0.593 | 3.630 | 4265.80 |
Hematology | 93 | 6 | 0.833 | 0.598 | 0.680 | 2.930 | 851.14 |
